肝移植等待名单上患者丙型肝炎治疗的最佳时机
该研究采用基于马尔可夫模型的微观模拟构建虚拟试验,比较MELD评分10至40分的失代偿期肝硬化患者在肝移植前与移植后使用口服直接抗病毒药物治疗丙型肝炎病毒的长期结局。模型预测,在全国层面,MELD≤27时移植前治疗可提高预期寿命,而MELD更高时可能降低预期寿命;不同联合国器官共享网络(UNOS)区域的治疗阈值在23至27之间波动。
要点
- 模型预测MELD≤27时移植前治疗丙型肝炎可提高预期寿命。
- MELD更高时移植前治疗可能降低预期寿命。
- 不同UNOS区域的移植前治疗MELD阈值在23至27之间。
核心结论
- 研究提示,失代偿期肝硬化患者在等待肝移植期间应接受丙型肝炎病毒治疗的最佳MELD阈值介于23至27之间,具体取决于UNOS区域。
研究设计与样本
- 基于马尔可夫模型的微观模拟研究,模拟MELD评分10至40分的肝移植等待名单患者及移植后的生命历程。
- 模拟整合了口服直接抗病毒药物近期试验(SOLAR 1和2)、UNOS及其他研究的数据。
- 模型预测的患者生存率用UNOS数据进行了验证。
主要发现
- 在全国层面,MELD≤27时移植前治疗丙型肝炎病毒可提高预期寿命,而MELD更高时可能降低预期寿命。
- 不同UNOS区域的移植前治疗MELD阈值在23至27之间变化,区域3、10和11较低,区域1、2、4、5、8和9较高。
- 敏感性分析显示上述阈值稳定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The availability of oral direct-acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both pre-liver transplant (LT) and post-LT patients. There is a perceived trade-off between pre-LT versus post-LT treatment of HCV-treatment may improve liver function but potentially decrease the likelihood of a necessary LT. Our objective was to identify LT-eligible patients with decompensated cirrhosis who would benefit (and not benefit) from pre-LT treatment based on their Model for End-Stage Liver Disease (MELD) scores. We simulated a virtual trial comparing long-term outcomes of pre-LT versus post-LT HCV treatment with oral direct-acting antivirals for patients with MELD scores between 10 and 40. We developed a Markov-based microsimulation model, which simulated the life course of patients on the transplant waiting list and after LT. Simulation of LT integrated data from recent trials of oral direct-acting antivirals (SOLAR 1 and 2), the United Network for Organ Sharing (UNOS), and other studies. The outcomes of the model included life expectancy, 1-year and 5-year patient survival, and mortality. Model-predicted patient survival was validated with UNOS data. We found that, at the national level, treating HCV before LT increased life expectancy if MELD was ≤27 but could decrease life expectancy at higher MELD scores. Depending on the UNOS region, the threshold MELD score to treat HCV pre-LT varied between 23 and 27 and was lower for UNOS regions 3, 10, and 11 and higher for regions 1, 2, 4, 5, 8, and 9. Sensitivity analysis showed that the thresholds were stable. CONCLUSION: Our findings suggest that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV treatment while awaiting LT is between 23 and 27, depending on the UNOS region. (Hepatology 2017;65:777-788).
引用
- Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017. PMID: 27906468. doi:10.1002/hep.28926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。